UCB BIOPHARMA SRL

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharamacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B

Phase 1

Completed

Conditions: Healthy Study Participants

Interventions: Drug: UCB0599
Other: Esomeprazole
Other: Placebo

First Posted Date: 2023-05-06

Last Posted Date: 2024-04-30

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 73

Registration Number: NCT05845645

Locations: 🇺🇸
Up0073 10001, Glendale, California, United States

A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)

Phase 3

Completed

Conditions: Generalized Myasthenia Gravis

Interventions: Drug: Rozanolixizumab

First Posted Date: 2023-01-12

Last Posted Date: 2024-05-23

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 62

Registration Number: NCT05681715

Locations: 🇷🇸
Mg0020 40729, NIS, Serbia
🇺🇸
Mg0020 50099, San Francisco, California, United States
🇮🇹
Mg0020 40150, Roma, Italy

and more 24 locations

A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome

Phase 2

Completed

Conditions: Fibromyalgia

Interventions: Drug: rozanolixizumab
Other: Placebo

First Posted Date: 2022-12-09

Last Posted Date: 2024-08-09

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 63

Registration Number: NCT05643794

Locations: 🇬🇧
Fm0001 4402, Manchester, United Kingdom
🇬🇧
Fm0001 4405, Blackpool, United Kingdom
🇬🇧
Fm0001 4406, Cannock, United Kingdom

and more 4 locations

A Relative Bioavailability Study of Staccato Alprazolam Versus Oral Alprazolam in Healthy Study Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Staccato alprazolam
Drug: Oral alprazolam

First Posted Date: 2022-11-23

Last Posted Date: 2024-03-18

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 21

Registration Number: NCT05626439

Locations: 🇺🇸
Up0104 1001, Baltimore, Maryland, United States

An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease

Phase 2

Conditions: Parkinson's Disease

Interventions: Drug: Minzasolmin (UCB0599)

First Posted Date: 2022-09-16

Last Posted Date: 2024-08-15

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 374

Registration Number: NCT05543252

Locations: 🇨🇦
Pd0055 50374, Calgary, Canada
🇨🇦
Pd0055 50387, Ottawa, Canada
🇨🇦
Pd0055 50389, Toronto, Canada

and more 93 locations

An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors

Phase 3

Completed

Conditions: Generalized Myasthenia Gravis

Interventions: Drug: zilucoplan (RA101495)

First Posted Date: 2022-08-25

Last Posted Date: 2024-10-30

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 26

Registration Number: NCT05514873

Locations: 🇺🇸
Mg0017 50593, Rancho Mirage, California, United States
🇺🇸
Mg0017 50304, Dallas, Texas, United States
🇺🇸
Mg0017 50086, Charlotte, North Carolina, United States

and more 9 locations

A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Male Japanese Study Participants

Phase 1

Completed

Conditions: Healthy Study Participants

Interventions: Drug: brivaracetam

First Posted Date: 2022-04-07

Last Posted Date: 2024-01-05

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 24

Registration Number: NCT05315947

Locations: 🇯🇵
EP0110 1, Sumida-ku, Japan

A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants

Phase 1

Completed

Conditions: Healthy Study Participants

Interventions: Drug: bimekizumab

First Posted Date: 2022-03-23

Last Posted Date: 2023-12-22

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 121

Registration Number: NCT05292131

Locations: 🇺🇸
UP0119 2, Glendale, California, United States
🇩🇪
UP0119 1, Berlin, Germany

A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)

Phase 1

Recruiting

Conditions: Atopic Dermatitis

Interventions: Biological: UCB1381
Drug: Placebo

First Posted Date: 2022-03-14

Last Posted Date: 2024-12-13

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 152

Registration Number: NCT05277571

Locations: 🇺🇸
Up0110 117, North Little Rock, Arkansas, United States
🇺🇸
Up0110 125, Beverly Hills, California, United States
🇺🇸
Up0110 101, Glendale, California, United States

and more 21 locations

A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Phase 3

Active, not recruiting

Conditions: Childhood Absence Epilepsy
Juvenile Absence Epilepsy

Interventions: Drug: Brivaracetam Film-coated tablet
Drug: Brivaracetam oral solution

First Posted Date: 2021-11-05

Last Posted Date: 2024-12-03

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 84

Registration Number: NCT05109234

Locations: 🇷🇴
Ep0132 562, Bucuresti, Romania
🇷🇴
Ep0132 563, Bucuresti, Romania
🇷🇴
Ep0132 560, Iasi, Romania

and more 24 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy